[go: up one dir, main page]

GR3026612T3 - Hepatitis a virus strain, method for the isolation of said virus strains and hepatitis a vaccines - Google Patents

Hepatitis a virus strain, method for the isolation of said virus strains and hepatitis a vaccines

Info

Publication number
GR3026612T3
GR3026612T3 GR980400808T GR980400808T GR3026612T3 GR 3026612 T3 GR3026612 T3 GR 3026612T3 GR 980400808 T GR980400808 T GR 980400808T GR 980400808 T GR980400808 T GR 980400808T GR 3026612 T3 GR3026612 T3 GR 3026612T3
Authority
GR
Greece
Prior art keywords
hepatitis
havs
relates
virus
vaccines
Prior art date
Application number
GR980400808T
Other languages
English (en)
Inventor
Reinhard Glueck
Stefan Brantschen
Original Assignee
Schweiz Serum & Impfinst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schweiz Serum & Impfinst filed Critical Schweiz Serum & Impfinst
Publication of GR3026612T3 publication Critical patent/GR3026612T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1009—Picornaviridae, e.g. hepatitis A virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GR980400808T 1991-05-08 1998-04-10 Hepatitis a virus strain, method for the isolation of said virus strains and hepatitis a vaccines GR3026612T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP91107526 1991-05-08
PCT/EP1992/001013 WO1992019268A1 (en) 1991-05-08 1992-05-08 New hepatitis a virus strain, method for the isolation of new hepatitis a virus strains and hepatitis a vaccines

Publications (1)

Publication Number Publication Date
GR3026612T3 true GR3026612T3 (en) 1998-07-31

Family

ID=8206711

Family Applications (2)

Application Number Title Priority Date Filing Date
GR930300089T GR930300089T1 (en) 1991-05-08 1993-09-30 Hepatitis a virus strain, method for the isolation of said virus strains and hepatitis a vaccines
GR980400808T GR3026612T3 (en) 1991-05-08 1998-04-10 Hepatitis a virus strain, method for the isolation of said virus strains and hepatitis a vaccines

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GR930300089T GR930300089T1 (en) 1991-05-08 1993-09-30 Hepatitis a virus strain, method for the isolation of said virus strains and hepatitis a vaccines

Country Status (10)

Country Link
EP (1) EP0542949B1 (el)
JP (1) JP3527238B2 (el)
AT (1) ATE163548T1 (el)
AU (1) AU662528B2 (el)
CA (1) CA2086832C (el)
DE (2) DE542949T1 (el)
DK (1) DK0542949T3 (el)
ES (1) ES2056780T3 (el)
GR (2) GR930300089T1 (el)
WO (1) WO1992019268A1 (el)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3523646B2 (ja) 1992-09-18 2004-04-26 スミスクライン・ビーチヤム・バイオロジカルズ・エス・エイ Ａ型肝炎ワクチン
US5766906A (en) * 1994-07-11 1998-06-16 The University Of North Carolina At Chapel Hill Hepatitis A virus deletion mutants and vaccine formulations containing the same
EP1802746B1 (en) 2004-10-27 2011-05-04 Crucell Switzerland AG Virosome particles comprising antigens from influenza virus and hepatitis b virus
CN116514965B (zh) * 2023-06-15 2023-11-10 上海精翰生物科技有限公司 甲型肝炎病毒抗体及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2398504A1 (fr) * 1977-07-29 1979-02-23 Tours Inst Virologie Culture de virus de l'hepatite a, in vitro. application a la production d'un antigene reactif, d'immunserums specifiques et de vaccins contre l'hepatite a
US4164566A (en) * 1978-08-17 1979-08-14 Merck & Co., Inc. Hepatitis a virus cell culture in vitro
CA1164799A (en) * 1979-09-04 1984-04-03 Paula A. Giesa Cell culture of hepatitis a virus

Also Published As

Publication number Publication date
JPH06500238A (ja) 1994-01-13
EP0542949A1 (en) 1993-05-26
DK0542949T3 (da) 1998-12-07
AU662528B2 (en) 1995-09-07
ATE163548T1 (de) 1998-03-15
CA2086832A1 (en) 1992-11-09
DE542949T1 (de) 1993-09-02
ES2056780T1 (es) 1994-10-16
EP0542949B1 (en) 1998-03-04
AU1743692A (en) 1992-12-21
JP3527238B2 (ja) 2004-05-17
GR930300089T1 (en) 1993-09-30
CA2086832C (en) 2007-05-01
DE69224590T2 (de) 1998-10-15
ES2056780T3 (es) 1998-08-16
WO1992019268A1 (en) 1992-11-12
DE69224590D1 (de) 1998-04-09

Similar Documents

Publication Publication Date Title
MY103182A (en) Vaccines against acquired immune deficiency syndrome.
CA2103887A1 (en) Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
EP0608261A4 (en) COMPOSITION OF AN IMMUNREACTIVE HEPATITIS C VIRUS POLYPEPTIDE.
NZ291153A (en) Determination of a specific antibody using multiple antigens containing several epitope regions which react with the antibody
EP0677533A3 (en) Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof
NO872581L (no) Et produksjon av antistoffer ved anvendelse av insolubil iserte immunkomplekser.
ES8404186A1 (es) "un procedimiento para obtener al menos un polipeptido que presenta la antigenicidad de los antigenos e del virus de la hepatitis b".
SK495A3 (en) Detection method of antibodies of hepatitis virus and set for detection of antibodies hcv
ATE127024T1 (de) Immunogene komplexe, insbesondere iscoms.
OA09802A (en) Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus.
HK1013849A1 (en) An augmented western blot format and immunoassay for detection of viral antibodies
JPS5740412A (en) Manufacture of virus antigen
Weiland et al. Development of monoclonal neutralizing antibodies against bovine viral diarrhea virus after pretreatment of mice with normal bovine cells and cyclophosphamide
GR3026612T3 (en) Hepatitis a virus strain, method for the isolation of said virus strains and hepatitis a vaccines
SG95574A1 (en) Immunoreactive antigens of hepatitia e virus
CA2080548A1 (en) Monoclonal antibodies to hepatitis c virus
GB9810756D0 (en) Mimotopes of hypervariable region 1 of the e2 glycoprotein of hcv and uses thereof
ES8609724A1 (es) Un inmunoensayo para detectar el anticuerpo del antigeno su-perficial-a de la hepatitis b
JPS5739350A (en) Preparation of toxoplasma antigen
NO953749L (no) Hepatitt B-escapemutantspesifikke bindingsmolekyler
CA2095735A1 (en) Monoclonal antibodies to hepatitis c virus and method for using same
DE69025629D1 (de) Arzneimittel und verfahren zur behandlung von erworbenem immundefizienzsyndrom (aids) und aids-verwandtem komplex unter verwendung von karbohydratspezifischen antikörpern
Wang et al. Isolation and adaptation characteristics of hepatitis a virus in primary african green monkey kidney cells: production of antigen useful for ELISA serology
Pervikov et al. Improvement of methods for intratypic differentiation of polioviruses: III. Neutralization test with cross-adsorbed sera for differentiation between wild and vaccine strains of polioviruses
JPS5344620A (en) Recovering of immobilized vaccine and specific antigen